For Immediate Release
For Further Information Contact:
Andrew Fisher at (202) 483-7000
Email: Afisher@unither.com

ADDITIONAL REMODULIN® EFFICACY AND SAFETY DATA PUBLISHED IN JOURNAL OF CARDIOVASCULAR PHARMACOLOGY

Research Triangle Park, NC, January 24, 2003: United Therapeutics Corporation (NASDAQ:UTHR) today announced that the article "Efficacy and Safety of Treprostinil: An Epoprostenol Analog for Primary Pulmonary Hypertension" has been published in the current issue of *THE JOURNAL OF CARDIOVASCULAR PHARMACOLOGY* in its current issue ((2003) Volume 41:2, p. 293).

"The data presented in this article further demonstrates the clinical utility of Remodulin in this patient population," said lead author, Vallerie McLaughlin, MD, Associate Professor of Medicine at Rush Presbyterian-St. Luke's Medical Center, Chicago, Illinois.

The article summarizes three pilot clinical trials that evaluated the effects of treprostinil (Remodulin) in the management of primary pulmonary hypertension. In the first trial, the intravenous prostacyclin epoprostenol (Flolan) and intravenous Remodulin were compared, while the second trial compared intravenous Remodulin and subcutaneous Remodulin. In the third trial, subcutaneous Remodulin was compared with placebo infusion during an eight-week period. In all three studies, patients with primary pulmonary hypertension receiving Remodulin had reductions in their pulmonary arterial pressures and experienced other favorable improvements in their hemodynamic measurements. In addition, patients receiving subcutaneous Remodulin during the eight-week study showed clinically significant improvement in their exercise capacity. Adverse effects reported (headache, diarrhea, flushing) were similar to those reported with chronic intravenous epoprostenol therapy; patients receiving chronic subcutaneous Remodulin infusions also reported erythema and pain at the infusion site.

"These studies recall the raison dêtre of our company -- offering the pulmonary hypertension community a longer-lasting alternative to intravenous prostacyclin," said Martine Rothblatt, Chairman and CEO of United Therapeutics.

Remodulin received United States Food and Drug Administration approval on May 21, 2002 as a continuous subcutaneous infusion for the treatment of pulmonary arterial hypertension in patients with NYHA Class II-IV, Canadian Therapeutic Products Directorate approval on October 4, 2002 and approval from the Israeli Ministry of Health on October 31, 2002. United Therapeutics has submitted marketing applications for Remodulin in France, Switzerland and Australia, with additional European filings to follow approval in France. In clinical trials, the most common side effects reported with Remodulin therapy included

infusion site pain (85%) and infusion site reaction (83%). Other adverse events included headache (27%), diarrhea (25%), nausea (22%), rash (14%), jaw pain (13%), vasodilatation (11%), dizziness (9%), edema (9%), pruritus (8%) and hypotension (4%). Remodulin should be used only by clinicians experienced in the diagnosis and treatment of pulmonary arterial hypertension.

United Therapeutics is a biotechnology company focused on combating chronic and life-threatening cardiovascular, infectious and oncologic diseases with unique therapeutic products.

* * *